Carl Zeiss Meditec


CZM’s eye attractiveness fades

18/06/24 -"Surprisingly, CZM slashed its full-year guidance yesterday. Greater Chinese exposure (marred by VBP roll-out delays and softer start to the summer peak season) and delayed interest rate cuts weighed ..."

Pages
69
Language
English
Published on
18/06/24
You may also be interested by these reports :
12/07/24
After integrating the latest figures, the higher EPS figure for 2023 results from improved granularity on the deconsolidation of FMC. Consequently, ...

12/07/24
We have huge doubts that FRE25 will achieve the planned profitability (group adjusted EBIT: 10-14%) by 2025 as there are numerous obstacles. The ...

03/07/24
The completion of the two capital increases has allowed Clariane to meaningfully strengthen the balance sheet, although financing challenges remain. ...

03/07/24
We have incorporated the second capital increase of €237m with preferential subscription rights following its completion. The number of shares has ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO